Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR ? and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).

Abstract: The invention provides modified Natural Killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex. These NK cells are used for T cell receptor (TCR) gene therapy in order to circumvent any risk of mispairing of the TCR a and ? chains and to provide Major Histocompatibility Complex (MHC)-restricted antigen-specific cytotoxicity to the NK cells. The invention additionally provides methods for producing the modified NK cells, therapeutic compositions including the modified NK cells, and methods for using the modified NK cells in therapy of cancer, viral infections, autoimmunity, and graft versus host disease (GvHD).

Abstract: A system for controlling extension and retraction of trailer landing gear of a trailer, with the landing gear including a shaft which is rotated to retract and extend the landing gear and the trailer further including a source of electricity. The system comprises: an electric motor having an output shaft disposed 90 degrees with respect to a longitudinal axis of the motor; a mounting plate affixable to the trailer landing gear, with the motor affixable to the mounting plate, the mounting plate sized and dimensioned to position the output shaft in axial alignment and adjacent to an end of the landing gear shaft, and to position the motor outboard of the trailer landing gear; and the motor connectable to the source of electricity to rotate and cause retraction or extension of the trailer landing gear.

Abstract: The invention provides methods for using F16 isoindole small molecules for treatment of solid tumors, particularly brain cancers, such as glioblastoma multiforme (GBM). F16 isoindole is an inhibitor of angiogenesis and is capable of antagonizing tumor vasculature. The invention also provides pharmaceutical compositions including F16 isoindole small molecules.

Abstract: Disclosed is mapping complex inflammatory mechanisms in (Gulf War Illness) GWI to improve understanding of the immunologic underpinnings of GWI, the compounding effects of co-morbidity with post-traumatic stress disorder, and the potential of this co-morbidity to define a unique subtype of GWI. Predictive modeling assesses possible changes to putative treatments of GWI in the context of a probable PTSD diagnosis or lack thereof. A logic model is constructed to represent the neuroimmune system across the blood-brain barrier (BBB) connecting the central nervous system to blood-based system. Next, the model results of a GWI cohort are topologically compared with and without PTSD symptoms to mouse models of GWI in blood and use the corresponding neuroimmune states in a mouse brain to infer the blood-brain state of GWI subjects. This inference is then used to guide predictive modeling of treatment courses designed to return the overall neuroimmune system to healthy regulation.

Abstract: Compositions include epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.

Abstract: A computer-based system, and a computer-implemented method, mentors students, particularly women and ethnic and racial minorities, intending to enter healthcare professions. The system uses a gamified mobile-enabled web application (App) that serves as a visual and interactive dashboard populated with checklists, career support resources, strategies, tips, and a mentoring platform to educate, encourage, empower, and facilitate the entry of students into the healthcare professions.

Abstract: The invention provides systems and methods for electronic coordination of healthcare. This healthcare coordination system is a digital platform for health providers and patients, providing user-friendly tools to navigate the continuum of healthcare services, particularly in chronic disease, such as diabetes or cancer. The invention also provides databases specific to a particular disease and/or population.

Abstract: Methods for using microRNA, particularly miRRA, to regulate nucleotide excision repair (NER) for treatment of cancer, particularly drug resistant breast cancer (BC) or late-stage breast cancer. The microRNA will effectively lower NER capacity in breast cancer, allowing for application or reapplication of chemotherapy that will be significantly more effective after pretreatment with the microRNA. Pharmaceutical compositions including microRNA are also provided.

Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.

Abstract: The invention provides sublingual epinephrine compositions including epinephrine fine particles formulated with pH-modifying excipients and penetration enhancers. The sublingual compositions are used to control absorption of epinephrine at the site of delivery in an oral cavity. The invention also provides methods for therapeutic use of the sublingual compositions for treatment of conditions responsive to epinephrine and/or for increasing sublingual bioavailability of epinephrine.

Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.

Abstract: A device for perimetry visual field testing of a patient includes a perimeter having a target fixation location; at least one video player positioned to display a video clip at the target fixation location; an audio clip player positioned to play one or more audio clips to be heard by the patient during visual field testing; and an electronic controller associated with the video display to cause a particular video clip to play during testing. The related method of visual field testing using a perimetry VF tester includes: positioning a video display at a fixation location within a perimeter of the tester; playing at least one video clips upon the video display during testing; and playing one or more audio clips corresponding to at least one of the video clip being displayed and a current stage of testing.

Abstract: An electronic processing system agent accesses population health literacy data from a population of at least 100 individuals pertaining to assessed health literacy of members of the population, and demographic data from the population corresponding to age, race, and level of education. The agent collects skills data from the patient corresponding to a set of questions presented to the patient relating to skills needed for understanding therapeutic instructions, as well as personal data relating to the age, race, and level of education of the patient.

Abstract: A general method of analyzing immune signaling networks for identification of potential therapeutic targets in complex, chronic medical disorders is described. The disclosure provides the CD3?/CD56+ natural killer (NK) cell population as a potential therapeutic target in the clinically-overlapping disorders Gulf War Illness (GWI) and Myalg Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The disclosure also provides a method for improving or restoring Natural Killer (NK) cell function by stimulating the NK cells with interleukin-15 (IL-15).

Abstract: In the detection of a complex multifactorial disease, an MN blood group typing is performed on a first blood sample of a subject to be tested for a complex multifactorial disease, and on a second blood sample of a control subject having known phenotypes. Erythrocytes from the samples are isovolumetrically sphered, and M alleles and N alleles expressed on surfaces of erythrocyte cells of the first and second blood samples are labeled by contacting the blood samples with anti-M antibodies and anti-N antibodies associated with a marker. Labeled M alleles and labeled N alleles in the first and second blood samples are detected and quantified using the marker, in order to determine an incidence of somatic mutations in Glycophorin A of the patient. The incidence is compared with data pertaining to patients with a known complex multifactorial disease, to diagnose the patient.

Abstract: The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

Abstract: The invention provides a method for compiling a genomic database for a complex disease, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and a method for using the database for identifying genetic patterns that can potentially categorize, diagnose, and/or predict therapeutics for the complex disease.

Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.